Pediatric Hodgkin Lymphoma

  • Zachary D. Guss
  • Qinyu Chen
  • Bradford Hoppe
  • Stephanie A. TerezakisEmail author
Part of the Practical Guides in Radiation Oncology book series (PGRO)


  • Hodgkin lymphoma represents approximately 4% of childhood (0–14 years old) malignancies and 15% of adolescent (15–19 years old) malignancies [1]. Bimodal incidence peaks in adolescent and adult age ranges [2].

  • The Reed-Sternberg cell, CD15+/CD30+, is a key histologic feature in classic subtypes (nodular sclerosing, lymphocyte-rich, lymphocyte-depleted, and mixed cellular) but not nodular lymphocyte predominant Hodgkin lymphoma (NLPHL).

  • Association with Epstein-Barr virus is highly variable (~30 to 40% in immunocompetent pediatric classical Hodgkin lymphoma, 80% + in immunocompromised patients) [3].

  • The radiation dose range in major North American trials has been 19.8–25.5 Gy in 1.5–1.8 Gy daily fractions, however, higher doses of 30 Gy are being employed among patients with imcomplete response following chemotherapy and in relapse studies.


  1. 1.
    Ward E, DeSantis C, Robbins A, Kohler B, Jemal A (2014) Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64(2):83–103CrossRefGoogle Scholar
  2. 2.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1):265–276CrossRefGoogle Scholar
  3. 3.
    Carbone A, Spina M, Gloghini A, Tirelli U (2011) Classical Hodgkin’s lymphoma arising in different host’s conditions: pathobiology parameters, therapeutic options, and outcome. Am J Hematol 86(2):170–179CrossRefGoogle Scholar
  4. 4.
    Zhou R, Ng A, Constine LS et al (2016) A comparative evaluation of normal tissue doses for patients receiving radiation therapy for Hodgkin lymphoma on the childhood cancer survivor study and recent Children’s Oncology Group trials. Int J Radiat Oncol Biol Phys 95(2):707–711CrossRefGoogle Scholar
  5. 5.
    Moskowitz CS, Chou JF, Wolden SL et al (2014) Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol 32(21):2217–2223CrossRefGoogle Scholar
  6. 6.
    Armstrong GT, Oeffinger KC, Chen Y et al (2013) Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31(29):3673–3680CrossRefGoogle Scholar
  7. 7.
    Meadows AT, Friedman DL, Neglia JP et al (2009) Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol 27(14):2356–2362CrossRefGoogle Scholar
  8. 8.
    Yahalom J, Mauch P (2002) The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol 13(Suppl 1):79–83CrossRefGoogle Scholar
  9. 9.
    Girinsky T, Specht L, Ghalibafian M et al (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88(2):202–210CrossRefGoogle Scholar
  10. 10.
    Dharmarajan KV, Friedman DL, Schwartz CL et al (2015) Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children’s Oncology Group. Int J Radiat Oncol Biol Phys 92(1):60–66CrossRefGoogle Scholar
  11. 11.
    Charpentier AM, Friedman DL, Wolden S et al (2016) Predictive factor analysis of response-adapted radiation therapy for chemotherapy-sensitive pediatric Hodgkin lymphoma: analysis of the Children’s Oncology Group AHOD 0031 trial. Int J Radiat Oncol Biol Phys 96(5):943–950CrossRefGoogle Scholar
  12. 12.
    Schwartz CL, Chen L, McCarten K et al (2016) Childhood Hodgkin International Prognostic Score (CHIPS) predicts event-free survival in Hodgkin lymphoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 64:e26278CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Zachary D. Guss
    • 1
  • Qinyu Chen
    • 1
  • Bradford Hoppe
    • 2
  • Stephanie A. Terezakis
    • 1
    Email author
  1. 1.Department of Radiation Oncology and Molecular Radiation SciencesJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Radiation OncologyUniversity of Florida HealthGainesvilleUSA

Personalised recommendations